MEDANTA1,457.00

Global Health Ltd.

· Pharma & Health
₹ CrorePeersMAXHEALTHAPOLLOHOSPFORTISGLAXOANTHEMAJANTPHARMIPCALABABBOTINDIAMcap ₹39,148 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)35.4831.0232.6832.68
Receivable Days (DSO)24.0028.8534.0334.03
Payable Days (DPO)99.1490.01100.2995.51
Cash Conversion Cycle (days)-39.66-30.14-33.58-28.80
Working Capital Turnover3.684.044.214.47
Asset Turnover0.760.770.750.75
Cash Conversion (CFO/Net Income)1.281.301.291.29
CFO/EBITDA0.770.710.780.78
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.